ABBV-295
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
AbbVie · Phase 1 · Active, not recruiting · Enrollment 80
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| ABBV-295 or Placebo-Group 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 3 Extension | Obesity or overweight | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 4 | Obesity or overweight | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 4 Extension | Obesity or overweight | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 5 | Obesity or overweight | n/r | n/r | n/r | n/r |
| ABBV-295 or Placebo-Group 6 | Obesity or overweight | n/r | n/r | n/r | n/r |